Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

Mozart Therapeutics has secured $55 million to develop celiac disease therapies. The Seattle-based biotech startup will use these funds for preclinical studies of the company’s lead compound.

“We have an opportunity to really do something different in autoimmune and inflammatory diseases,” said Katie Fanning, CEO of Mozart Therapeutics.

READ THE STORY at GeekWire »